Drawing for OCUSEVA

USPTO serial 79087956

OCUSEVA

Reviewed by CopyMark Law Group

Reg. 4123512Status 404
Filing date
Status date
Registration date
Apr 10, 2012
Examiner
EINSTEIN, MATTHEW T
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with OCUSEVA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Sandra Edelman

Sandra Edelman Dorsey & Whitney LLP51 West 52nd StreetNew York, NY 10019-6119UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Ophthalmic pharmaceutical preparations for treatment of retinal diseases, glaucoma and ocular hypertensionSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 13, 2021DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Nov 13, 2021DETHDEATH OF INTERNATIONAL REGISTRATION—
Nov 29, 2019INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Aug 6, 2019INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Aug 6, 2019INPCINVALIDATION PROCESSED—
Jul 16, 2019INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Nov 16, 2018C71TCANCELLED SECTION 71—
Apr 10, 2017REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Oct 6, 2016ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 6, 2016REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jan 29, 2015NREPNEW REPRESENTATIVE AT IB RECEIVED—
Apr 10, 2014NREPNEW REPRESENTATIVE AT IB RECEIVED—
Aug 17, 2012FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jul 30, 2012FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jul 30, 2012FIMPFINAL DISPOSITION PROCESSED—
Jul 10, 2012FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Apr 10, 2012R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 7, 2012TMBNTTAB RELEASE CASE TO TRADEMARKS—
Mar 7, 2012OP.TOPPOSITION TERMINATED NO. 999999—
Mar 7, 2012OP.DOPPOSITION DISMISSED NO. 999999—
Feb 21, 2012MAILPAPER RECEIVED—
Jun 11, 2011RFNPREFUSAL PROCESSED BY IB—
May 21, 2011OP.IOPPOSITION INSTITUTED NO. 999999—
May 20, 2011OPNSOPPOSITION NOTICE (IB REFUSAL) SENT TO IB—
May 20, 2011OPNCOPPOSITION NOTICE (IB REFUSAL) CREATED—
Apr 1, 2011ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Mar 8, 2011PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 3, 2011OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 3, 2011OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Feb 16, 2011NPUBNOTICE OF PUBLICATION—
Jan 6, 2011CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 4, 2011DOCKASSIGNED TO EXAMINER—
Nov 6, 2010MAFRAPPLICATION FILING RECEIPT MAILED—
Nov 2, 2010NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 29, 2010LIMSLIMITATION OF GOODS/SERVICES FROM IB ENTERED—
Oct 28, 2010REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance